醫思健康(02138.HK)中期權益股東應占溢利1410萬港元 同比增長112%
格隆匯11月28日丨醫思健康(02138.HK)公佈中期業績,截至2024年9月30日止6個月,集團錄得收入及銷售額分別20.629億港元及20.844億港元,分別較同比下降2.8%及4.4%。收入及銷售額輕微下降綜合歸因於醫療分部、美學醫療、美容及養生分部貢獻有所減少,有關分部為可自行選擇的相關服務,受不利市場氣氛及香港市民在深圳跨境消費趨勢影響,並抵銷獸醫及其他服務分部貢獻的增幅。
儘管收入輕微下降,惟報吿期間集團的税後淨溢利同比增加88.1%至4030萬港元,公司權益股東應占溢利則同比增加112.0%至1410萬港元。其增加主要原因乃(i)與截至2024年3月31日及2023年3月31日止過往財政年度相比,我們新設立的服務點營運效率有所提高;(ii)總部租金及員工開支方面的成本優化;及(iii)淨利息開支減少(即利息開支減去利息收入)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.